JNJ 48816274
Alternative Names: JNJ-48816274Latest Information Update: 28 Oct 2019
At a glance
- Originator Janssen-Cilag
- Class Sleep disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Insomnia
Most Recent Events
- 28 Oct 2019 No recent reports of development identified for phase-I development in Insomnia(In volunteers) in United Kingdom (PO)
- 02 May 2018 Janssen-Cilag completes a phase I trial in Insomnia (In volunteers) in United Kingdom (PO) (NCT02852395)
- 28 Jul 2016 Janssen-Cilag International plans a first-in-human phase I trial in Healthy volunteers in USA (PO) (NCT02852395)